Clinical trial · Observational
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
The Role of the Comprehensive Geriatric Assessment in Elderly Patients With Multiple Myeloma: A Single Center Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Plasma Cell Myeloma | Multiple Myeloma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Comprehensive Geriatric Assessment | Other | — | UNRESOLVED |
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (Surveys, cGA, blood sample, EHR review)
- description
- Patients complete surveys and undergo cGA, blood sample collection, and EHR review on study.
- interventionNames
- Procedure: Biospecimen Collection
- Other: Comprehensive Geriatric Assessment
- Other: Electronic Health Record Review
- Other: Survey Administration
Primary outcomes (1)
- measure
- Incidence of treatment-related adverse events
- timeFrame
- Up to 4 months
- description
- Will graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The maximum observed grade per adverse event and capture grade \>= 3 toxicities.
Secondary outcomes (3)
- measure
- Chemotherapy toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>= 65 years * Diagnosis of MM based on International Myeloma Working Group (IMWG) diagnostic criteria * Newly diagnosed or have received 1 prior line of treatment * Planned to start a new treatment for MM within 30 days * Transplant eligible or ineligible * Fluent in English (all assessment tools are in English) * Able to provide written informed consent Exclusion Criteria: * Received \> 1 prior line of treatment * Patients included in an interventional therapeutic trial * Not able to give informed consent * Severe mental or cognitive disorder precluding geriatric assessment
References
Publications (0)
Data not yet available